Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy

Acta Radiologica

Volumn 53, Issue 2, 2012, Pages 127-134

  Liu, Kun ^a   Li, Guoli ^a   Fan, Chaogang ^a   Zhou, Changsheng ^a   Li, Jieshou ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Choi criteria; Contrast enhanced CT; Locally advanced gastric cancer; RECIST; Tumor attenuation; Tumor response

Indexed keywords

CHOI CRITERIA; CONTRAST-ENHANCED CT; GASTRIC CANCERS; RECIST; TUMOR RESPONSE;

BODY FLUIDS; CHEMOTHERAPY; COMPUTERIZED TOMOGRAPHY; DISEASES; ENZYME INHIBITION; FORECASTING; PATIENT MONITORING;

TUMORS;

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; DIAGNOSTIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; IMAGE QUALITY; LYMPH NODE; LYMPH NODE METASTASIS; MALE; METHODOLOGY; MIDDLE AGED; OBSERVER VARIATION; PREDICTIVE VALUE; PREOPERATIVE CARE; RADIOGRAPHY; RETROSPECTIVE STUDY; STOMACH TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; RADIOGRAPHIC IMAGE ENHANCEMENT; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84858811880     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1258/ar.2011.110273     Document Type: Review

References (28)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108 (Pubitemid 40372904)
2. Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005;2:98-107 (Pubitemid 40790143)
3. Siewert JR, Sendler A. The current management of gastric cancer. Adv Surg 1999;33:69-93
4. D'Angelica M, Gonen M, Brennan MF, et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004;240:808-16 (Pubitemid 39425773)
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
6. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031-9
7. Curran SD, Muellner AU, Schwartz LH. Imaging response assessment in oncology. Cancer Imaging 2006;6:S126-30
8. Holdsworth CH, Badawi RD, Manola JB, et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. Am J Roentgenol 2007;189:W324-30
9. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-4 (Pubitemid 46797958)
10. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am J Roentgenol 2004;183:1619-28 (Pubitemid 44210530)
11. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-9 (Pubitemid 46797957)
12. Stacchiotti S, Collini P, Messina A, et al. High-grade soft-tissue sarcomas: tumor response assessment-pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 2009;251:447-56
13. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004;22:4442-5 (Pubitemid 41185107)
14. De Vita F, Giuliani F, Orditura M, et al. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol 2007;18:1354-8 (Pubitemid 47305009)
15. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30
16. Cascinu S, Labianca R, Barone C, et al. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 2007;99:601-7 (Pubitemid 47073541)
17. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. Am J Roentgenol 2010;194:157-65
18. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009;302:2338-44
19. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8:595-602 (Pubitemid 46995623)
20. Miles KA. Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur J Radiol 1999;30:198-205 (Pubitemid 29343737)
21. Miles KA, Charnsangavej C, Lee FT, et al. Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 2000;7:840-50
22. Dawson P. Functional imaging in CT. Eur J Radiol 2006;60:331-40
23. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6 (Pubitemid 20020880)
24. Lee SM, Kim SH, Lee JM, et al. Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer. Abdom Imaging 2009;34:430-40
25. Baghi M, Mack MG, Hambek M, et al. Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy. Head Neck 2007;29:104-8 (Pubitemid 46167776)
26. Schuetze SM, Baker LH, Benjamin RS, et al. Selection of response criteria for clinical trials of sarcoma treatment. Oncologist 2008;13 (Suppl. 2): 32-40
27. McNitt-Gray MF, Bidaut LM, Armato SG, et al. Computed tomography assessment of response to therapy: tumor volume change measurement, truth data, and error. Transl Oncol 2009;2:216-22
28. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010;102:803-9